Q1: 2026-05-05 Earnings Summary
EPS of $6.34 beats by $1.68
|
Revenue of
$1.07B
(19.05% Y/Y)
beats by $89.89M
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDT
Company Participants
John Bluth - Head of Investor Relations
Renée Galá - President, CEO & Director
Samantha Pearce - Executive VP & Chief Commercial Officer
Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development
Philip Johnson - Executive VP & CFO
Conference Call Participants
Jessica Fye - JPMorgan Chase & Co, Research Division
Joseph Thome - TD Cowen, Research Division
Leonid Timashev - RBC Capital Markets, Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Marc Goodman - Leerink Partners LLC, Research Division
Jordan Becker - Barclays Bank PLC, Research Division
Charles Moore - Robert W. Baird & Co. Incorporated, Research Division
David Amsellem - Piper Sandler & Co., Research Division
Mohit Bansal - Wells Fargo Securities, LLC, Research Division
Jason Gerberry - BofA Securities, Research Division
Ami Fadia - Needham & Company, LLC, Research Division
David Hoang - Deutsche Bank AG, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2026 First Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker for today, John Bluth, Head of Investor Relations. Please go ahead.
John Bluth
Head of Investor Relations
Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its first quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website, along with the press release and quarterly report on Form 10-Q for the first quarter ended March 31, 2026. On the call today are Renee Gala, President and Chief Executive Officer; Sam Pearce, Chief Commercial Officer; Robbie Iannone, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Chief Financial Officer.
On Slide
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。